Literature DB >> 8699074

Changes in virus load markers during AIDS-associated opportunistic diseases in human immunodeficiency virus-infected persons.

R M Donovan1, C E Bush, N P Markowitz, D M Baxa, L D Saravolatz.   

Abstract

Human immunodeficiency virus (HIV) load markers are being used increasingly to monitor disease progression and evaluate antiretroviral therapy. This study examined plasma HIV RNA and p24 antigen levels before, during, and after 15 AIDS-associated opportunistic disease events in patients with AIDS (median CD4 cell count = 65/microL). Plasma HIV RNA was detected during 13 of the 15 events (median level before an event = 21,000 copies/mL). There was an increase in the level of plasma HIV RNA with the onset of an AIDS-associated opportunistic disease during 11 of 13 events for which HIV RNA was detectable (median level during an event = 145,000 copies/mL). There was a decline in the level of HIV RNA with the recovery from disease (median level after an event = 29,700 copies/mL). In contrast, there was no consistent or significant change in p24 antigen levels or CD4 cell counts with either the onset of or recovery from an event. Clinical interpretation of plasma HIV RNA changes must take into account this reversible elevation during AIDS-associated opportunistic disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8699074     DOI: 10.1093/infdis/174.2.401

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  20 in total

1.  Comparison of the frequencies and levels of human immunodeficiency virus type 1 markers in specimens from chronically infected human T-lymphocyte cultures and from patients.

Authors:  D J Witt; C C Ginocchio; X P Wang; M K Kaufman
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

2.  The effects of early syphilis on CD4 counts and HIV-1 RNA viral loads in blood and semen.

Authors:  S T Sadiq; J McSorley; A J Copas; J Bennett; S J Edwards; S Kaye; S Kirk; P French; I V D Weller
Journal:  Sex Transm Infect       Date:  2005-10       Impact factor: 3.519

3.  The Interaction between HIV and malaria in Africa.

Authors:  Miriam K Laufer; Christopher V Plowe
Journal:  Curr Infect Dis Rep       Date:  2007-01       Impact factor: 3.725

4.  Surrogate markers now provide physicians with the best means to manage antiretroviral therapy: the case for.

Authors:  G J Moyle; B G Gazzard; T Peto
Journal:  Genitourin Med       Date:  1997-06

5.  Rapid microfluidic immunoassay for surveillance and diagnosis of Cryptosporidium infection in human immunodeficiency virus-infected patients.

Authors:  Li Zhang; Yongfeng Fu; Wenwen Jing; Qing Xu; Wang Zhao; Meng Feng; Hiroshi Tachibana; Guodong Sui; Xunjia Cheng
Journal:  Biomicrofluidics       Date:  2015-04-14       Impact factor: 2.800

6.  Reduced concentrations of HIV-RNA and TNF-alpha coexist in CSF of AIDS patients with progressive multifocal leukoencephalopathy.

Authors:  L Monno; G B Zimatore; M Di Stefano; A Appice; P Livrea; G Angarano
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

7.  [BNP in HIV-infected patients].

Authors:  Till Neumann; Nico Reinsch; Kathrin Neuhaus; Norbert Brockmeyer; Anja Potthoff; Stefan Esser; Martin Hower; Anja Neumann; Sarah Mostardt; Götz Gelbrich; Raimund Erbel
Journal:  Herz       Date:  2009-12       Impact factor: 1.443

Review 8.  Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection.

Authors:  S D Lawn; S T Butera; T M Folks
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

9.  Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapy.

Authors:  Laura E Jones; Alan S Perelson
Journal:  J Acquir Immune Defic Syndr       Date:  2007-08-15       Impact factor: 3.731

10.  Mycobacterium avium complex augments macrophage HIV-1 production and increases CCR5 expression.

Authors:  S M Wahl; T Greenwell-Wild; G Peng; H Hale-Donze; T M Doherty; D Mizel; J M Orenstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.